278 related articles for article (PubMed ID: 11172670)
21. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Dai L; Lin Z; Qiao J; Chen Y; Flemington EK; Qin Z
Oncogene; 2017 Aug; 36(35):5068-5074. PubMed ID: 28459467
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Yen Y; Margolin K; Doroshow J; Fishman M; Johnson B; Clairmont C; Sullivan D; Sznol M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):331-42. PubMed ID: 15148626
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.
Jiang ZG; Lebowitz MS; Ghanbari HA
CNS Drug Rev; 2006; 12(1):77-90. PubMed ID: 16834759
[TBL] [Abstract][Full Text] [Related]
24. Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.
Kunos CA; Radivoyevitch T; Ingalls ST; Hoppel CL
Future Oncol; 2012 Feb; 8(2):145-50. PubMed ID: 22335579
[TBL] [Abstract][Full Text] [Related]
25. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Yu Y; Suryo Rahmanto Y; Hawkins CL; Richardson DR
Mol Pharmacol; 2011 Jun; 79(6):921-31. PubMed ID: 21389104
[TBL] [Abstract][Full Text] [Related]
26. New Iminodiacetate-Thiosemicarbazone Hybrids and Their Copper(II) Complexes Are Potential Ribonucleotide Reductase R2 Inhibitors with High Antiproliferative Activity.
Zaltariov MF; Hammerstad M; Arabshahi HJ; Jovanović K; Richter KW; Cazacu M; Shova S; Balan M; Andersen NH; Radulović S; Reynisson J; Andersson KK; Arion VB
Inorg Chem; 2017 Mar; 56(6):3532-3549. PubMed ID: 28252952
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
Krishnan K; Prathiba K; Jayaprakash V; Basu A; Mishra N; Zhou B; Hu S; Yen Y
Bioorg Med Chem Lett; 2008 Dec; 18(23):6248-50. PubMed ID: 18976907
[TBL] [Abstract][Full Text] [Related]
28. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Lin ZP; Belcourt MF; Cory JG; Sartorelli AC
J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505
[TBL] [Abstract][Full Text] [Related]
29. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
Shao J; Zhou B; Di Bilio AJ; Zhu L; Wang T; Qi C; Shih J; Yen Y
Mol Cancer Ther; 2006 Mar; 5(3):586-92. PubMed ID: 16546972
[TBL] [Abstract][Full Text] [Related]
30. Development of ribonucleotide reductase inhibitors: a review on structure activity relationships.
Moorthy NS; Cerqueira NM; Ramos MJ; Fernandes PA
Mini Rev Med Chem; 2013 Nov; 13(13):1862-72. PubMed ID: 24032510
[TBL] [Abstract][Full Text] [Related]
31. alpha-N-heterocyclic thiosemicarbazone derivatives as potential antitumor agents: a structure-activity relationships approach.
Matesanz AI; Souza P
Mini Rev Med Chem; 2009 Oct; 9(12):1389-96. PubMed ID: 19929812
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.
Aye Y; Long MJC; Stubbe J
J Biol Chem; 2012 Oct; 287(42):35768-35778. PubMed ID: 22915594
[TBL] [Abstract][Full Text] [Related]
33. Metal complexes of 3-(4-bromophenyl)-1-pyridin-2-ylprop-2-en-1-one thiosemicarbazone: cytotoxic activity and investigation on the mode of action of the gold(III) complex.
Sâmia LB; Parrilha GL; Da Silva JG; Ramos JP; Souza-Fagundes EM; Castelli S; Vutey V; Desideri A; Beraldo H
Biometals; 2016 Jun; 29(3):515-26. PubMed ID: 27091443
[TBL] [Abstract][Full Text] [Related]
34. Comparative cytotoxic and biochemical effects of ligands and metal complexes of alpha-N-heterocyclic carboxaldehyde thiosemicarbazones.
Saryan LA; Ankel E; Krishnamurti C; Petering DH; Elford H
J Med Chem; 1979 Oct; 22(10):1218-21. PubMed ID: 513069
[TBL] [Abstract][Full Text] [Related]
35. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
Nocentini G; Federici F; Franchetti P; Barzi A
Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
[TBL] [Abstract][Full Text] [Related]
36. Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.
Stefani C; Jansson PJ; Gutierrez E; Bernhardt PV; Richardson DR; Kalinowski DS
J Med Chem; 2013 Jan; 56(1):357-70. PubMed ID: 23276209
[TBL] [Abstract][Full Text] [Related]
37. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
39. Ribonucleotide reductase inhibitors and future drug design.
Shao J; Zhou B; Chu B; Yen Y
Curr Cancer Drug Targets; 2006 Aug; 6(5):409-31. PubMed ID: 16918309
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of ribonucleotide reductase by alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones.
Moore EC; Sartorelli AC
Pharmacol Ther; 1984; 24(3):439-47. PubMed ID: 6379688
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
